Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purethal
- Development stage
- Phase 4
- Lead developer
- HAL Allergy
- Modality
- Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Purethal is a brand of allergen immunotherapy products developed for the treatment and prevention of allergic diseases such as allergic rhinitis (hay fever), allergic conjunctivitis, and hypersensitivity reactions. The product line includes formulations targeting specific allergens like grass pollen (Purethal Grasses) and house dust mites (PURETHAL Mites). These are therapeutic vaccines that work by gradually exposing patients to increasing doses of allergen extracts via subcutaneous injection, thereby stimulating the immune system to develop tolerance to these allergens. This process reduces symptoms upon natural exposure. The mechanism of action is immunostimulation through controlled allergen exposure. Purethal is primarily indicated for IgE-mediated allergies confirmed by diagnostic testing[7][9].
- Brand names
- PurethalPurethal GrassesPURETHAL Mites
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on Purethal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Purethal.